Biocryst Pharmaceuticals (BCRX) Revenue Growth (3y) (2013 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.04 Bn | 198.05 Bn | 7.24 Bn | 12.90% |
| 2 | Gilead Sciences | 181.35 Bn | 178.17 Bn | 6.22 Bn | 5.75% |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn | 10.17% |
| 4 | Regeneron Pharmaceuticals | 82.94 Bn | 74.94 Bn | 3.93 Bn | 10.76% |
| 5 | Argenx Se | 61.53 Bn | 56.34 Bn | 1.37 Bn | 77.85% |
| 6 | Moderna | 54.25 Bn | 49.11 Bn | 52.00 Mn | -25.02% |
| 7 | Alnylam Pharmaceuticals | 34.41 Bn | 31.10 Bn | 992.69 Mn | 59.40% |
| 8 | Biogen | 31.19 Bn | 29.91 Bn | 1.96 Bn | 3.66% |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | - |
| 10 | Biocryst Pharmaceuticals | 2.31 Bn | 1.95 Bn | 214.41 Mn | 38.31% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 38.31% |
| Mar 31, 2026 | 31.50% |
| Dec 31, 2025 | -79.28% |
| Sep 30, 2025 | 28.10% |
| Jun 30, 2025 | 35.59% |
| Mar 31, 2025 | 42.85% |
| Dec 31, 2024 | 40.76% |
| Sep 30, 2024 | 41.88% |
| Jun 30, 2024 | 29.83% |
| Mar 31, 2024 | 69.47% |
| Dec 31, 2023 | 185.44% |
| Sep 30, 2023 | 142.24% |
| Jun 30, 2023 | 206.28% |
| Mar 31, 2023 | 142.50% |
| Dec 31, 2022 | 26.04% |
| Sep 30, 2022 | 249.58% |
| Jun 30, 2022 | 256.36% |
| Mar 31, 2022 | 103.92% |
| Dec 31, 2021 | 158.53% |
| Sep 30, 2021 | 204.36% |